Table 1.
Clinical information on tumor samples
| PMP grade | CCRa | Previous clinical history | Prior chemotherapy | PCI score |
|---|---|---|---|---|
| PMP3 (high‐grade PMP with signet cells)b | R2C | Right hemicolectomy/HIPEC | FOLFIRI, Avastin, chemo | >20 |
| PMP1 (low‐grade PMP or DPAM) | R1 | Prior debulking | No chemotherapy | <16 |
| PMP1 (low‐grade PMP or DPAM) | R1 | No prior treatment | No chemotherapy | <16 |
| PMP1 (low‐grade PMP or DPAM) | R1 | No prior treatment | No chemotherapy | <16 |
| PMP1 (low‐grade PMP or DPAM) | R2C pelvis | Multiple debulking | Partial debulking for symptoms could not tolerate chemotherapy | >20 |
| PMP1 (low‐grade PMP or DPAM) | R1 | Prior debulking | No chemotherapy | <16 |
PMP, pseudomyxoma peritonei; CCR, completeness of cytoreduction; DPAM, disseminated peritoneal adenomucinosis; PCI, peritoneal cancer index.
a
The level of cytoreduction was scored as follows: R1, no visible disease; R2a, residual tumor nodules ≤5 mm; R2b, residual tumor nodules >5 mm but ≤2 cm; R2c, residual tumor nodules >2 cm; and R3, unresectable tumor nodules.
b
Initial pathology was DPAM (low‐grade PMP or PMP1) and lymph node negative; cytoreductive surgery with hyperthermic intraperitoneal chemotherapy; recurred with signet cells.